• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva announces two offerings worth $7.5 billion, dips on missed Q3 projections

October 27, 2021 By Sean Whooley

TevaTeva Pharmaceuticals (NYSE:TEVA) shares took a hit today on third-quarter results that fell short of the consensus forecast.

TEVA shares were down -4.7% at $8.95 per share in mid-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%.

The Tel Aviv, Israel-based company posted profits of $292 million, or 26¢ per share, on sales of $3.9 billion for the three months ended Sept. 30, 2021, for a massive bottom-line gain from losses of -4.3 billion this time last year on a sales decline of -2.5%.

Adjusted to exclude one-time items, earnings per share were 59¢, 6¢ behind Wall Street, where analysts were looking for sales of $4 billion.

“I am very happy with our solid performance in the third quarter of 2021, especially our strong cash flow and continued momentum with key brands,” Teva President & CEO Kåre Schultz said in a news release. “Our results were driven by robust performance of Ajovy in the U.S., Europe and Japan as well as U.S. sales of Austedo, our novel therapy for the treatment of patients with Huntington’s disease and tardive dyskinesia.

“We are also very enthusiastic about expanding our pipeline with additional movement disorder products in clinical development for multiple system atrophy (MSA) and Parkinson’s disease, through the strategic collaboration announced yesterday with Modag GmbH.”

Teva reaffirmed its outlook with expectations to log adjusted EPS of between $2.50 and $2.70 in 2021. The company projects revenues between $16 billion and $16.4 billion.

In addition to announcing its earnings, Teva confirmed its intent to issue sustainability-linked senior notes worth $4 billion, as well as debt tender notes worth up to $3.5 billion.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, MassDevice Earnings Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS